Acclinate-logo
Talk to Our Team

According to a recent study published in the journal Gastroenterology, Blacks and Hispanics remain noticeably absent from pancreatic cancer clinical trials. In fact, data showed that the actual inclusion of racial and ethnic minorities has stayed flat over 15 years. This research mirrors other studies revealing that Black and Hispanic races are consistently underrepresented in oncology trials compared with their burden of cancer incidence. And the problem of clinical trial diversity is not exclusive to oncology trials. For example, the American Diabetes Association recently highlighted large disparities in racial and ethnic representation among pivotal type 1 diabetes trials used to gain FDA approval, even more concerning given that rates of type 1 diabetes are increasing in underrepresented groups.

Pharmacogenomics informs us that people of different races and ethnicities may have different reactions to pharmaceuticals, so having a diverse population participate in trials helps ensure the safety and efficacy of new medications. Inclusive research also enables more patients to benefit from therapies that can improve their quality of life. However, as the two studies point out, the lack of racial and ethnic diversity in clinical trials is not new. For better or worse, COVID and the associated social justice movements have put a spotlight on long-standing health inequities, including clinical trial diversity. Fortunately, we have witnessed the FDA, pharmaceutical companies, CROs, and academic medical centers all moving the issue of clinical trial diversity toward the front of the priority line. 

But why are clinical trial diversity initiatives still falling short of their expected goal even after all this attention and shifting of priorities? 

New Approaches, Same Flaw

The guidance issued last year by the FDA, “Enhancing the Diversity of Clinical Trial Populations--Eligibility Criteria, Enrollment Practices, and Trial Designs,” provides recommendations for how sponsors can increase enrollment of underrepresented populations in their clinical trials, including steps to broaden eligibility criteria in clinical trials through inclusive trial practices, trial designs, and methodological approaches. 

Several groups have focused on helping clinicians understand communication gaps that impede trial enrollment while helping patients gain insights into the value of clinical trials. Still, others are taunting the momentum of decentralized clinical trials (DCT) as the swift answer to clinical trial diversity. The rapid adoption of DCT due to the COVID-19 pandemic has revealed numerous benefits, including reducing barriers such as transportation and limited site access, accelerating clinical trial timelines, streamlining clinical operations, and reducing patient and investigator burden. However, the verdict is still out as to whether DCT is the answer for clinical trial diversity. It is likely that decentralized trials will help, but it will not solve the representation challenge in clinical trials. 

A lapse in DCT trials is that they are less likely to be held in black communities where residents might be more likely and willing to participate.  Even though DCT trials make a concerted effort to provide resources like transportation and increased access, another missing component may be the presence of nurses and administrators of color who understand the daily lifestyle of minority participants and who are better equipped to properly communicate with them.  

Many of these approaches presume that the primary deterrent of clinical trial diversity centers on issues of protocol design, education, or access. These approaches underestimate the importance of affective trust when it comes to getting a potential participant to say “yes, I want to participate” through an informed consent process. ‍

Not All Trust is Equal

Cognitive trust occurs when a person makes a conscious decision to trust-based upon the best knowledge he or she has. When interactions are based on cognitive trust, individuals choose to trust based on evidence of trustworthiness. Thus, cognitive trust tends to be high when repeated interactions allow parties to come to know, understand, and predict one another. Affective trust, on the other hand, develops when individuals emotionally invest in relationships, resulting in genuine concern for each other's wellbeing. As such, affective trust resides at an interpersonal level. 

Here is an illustration of affective trust. You have a persistent cold. A quick WebMD search relays various courses of action recommended by a pulmonologist. You decide to call your grandmother who says, “just put some Vicks on your chest”.  Because you know your grandmother has a genuine concern for you and your best interest, despite not being an MD, you lean toward the Vicks approach. Unfortunately, these are not isolated occurrences.  People in communities of color handle medical situations as illustrated because of the inherent lack of trust in the medical community. 

At the least, building cognitive trust has to become a priority in order to establish relationships between industry and minority communities. For most in those communities, both history and present interactions have further widened the chasm of trust.

So the question becomes: How do you repair that trust? ‍

How Does this Apply to Clinical Trial Diversity?

As the adage goes, “People don't care how much you know, until they know how much you care.” The question that racial and ethnic minorities are implicitly wondering is whether, regardless of if they participate in a trial or not, researchers and practitioners will still care about their health and subsequently do what’s best for them. Communities of color are looking at pharmaceutical companies, CROs, and academic medical centers conducting clinical trials to ultimately answer this question. Even still, they don’t quite understand or trust them.  To start to build, and eventually gain trust, the pharmaceutical industry can use innovation to address this fundamental flaw. Industry does not currently possess the innovation itself so it is incumbent that it builds relationships with innovators who have identified ways to build effective trust with communities of color.‍

What is the Solution to the Lack of Diversity in Clinical Trials?

Acclinate is the solution. The company serves as a bridge between communities and medical entities. Acclinate is able to help clinical trial sponsors save time, save money, and accelerate the time to market using a two-prong approach.  First, #NOWINCLUDED is the growing network of minorities who are provided with education, story-telling, and ongoing conversation so that they are able to learn more about and be encouraged to participate in medical research. Secondly, the #NOWINCLUDED network data feeds into Acclinate’s HIPAA-compliant software platform, known as e-DICT™ (Enhanced Diversity in Clinical Trials). E-DICT uses predictive analytics and machine learning to identify the people who are most willing and likely to participate in clinical trials.

Essentially, #NOWINCLUDED does the front-end work of engaging and educating the community so they are empowered to participate. On the back end, E-DICT connects the industry with the people who want to be included as part of the solution.

To learn more about how Acclinate increases affective trust with communities of color so they are more likely to participate in clinical trials, request a demo.

Recent Posts

Unpacking the Latest FDA Guidance: Diversity in Clinical Trials for Pharma
3 Min Read

Earlier this year, the U.S. Food and Drug Administration updated its guidance document on collecting race and ethnicity data in clinical trials. The d...

Read More
Clinical Trial Recruitment Strategies that Increase Diversity
3 Min Read

Under 2022’s Food and Drug Omnibus Reform Act, clinical trial sponsors are required tosubmit diversity action plans with pivotal drug studies such as ...

Read More
Using Clinical Trial Services to Connect with Communities of Color
4 Min Read

Clinical research requires trust between the patient and the pharmaceutical companies. When that trust has been damaged, patients will avoid participa...

Read More
Overcome Clinical Trial Recruitment Challenges: Start with Affective Trust
4 Min Read

Inclusive clinical research populations are necessary for a successful study, and new laws are beginning to mandate diversity action plans to promote ...

Read More
Marques Bradley: Coding for a Cause at Acclinate
2 Min Read

When Marques Bradley joined Acclinate amidst the pandemic's uncertainty in October of 2020, it wasn't just another job opportunity; it was a call to m...

Read More
1 Min Read

As we celebrate our four-year anniversary, Acclinate stands at the forefront of a crucial revolution in healthcare—empowering communities of color to ...

Read More
The Consequences of a Lack of Diversity in Clinical Trials
3 Min Read

Your clinical research processes are carefully developed over the years, and the success of your project depends on thoughtful preparation. As pharmac...

Read More
Why Diversity, Equity, and Inclusion in Healthcare Is Vital
4 Min Read

In recent years, organizations in all industries have increased their emphasis on diversity, equity, and inclusion (DE&I). In healthcare, the adde...

Read More
Nurturing Health Equity: A Black History Month Reflection
1 Min Read

As we enter Black History Month, Acclinate proudly reaffirms its commitment to health equity—a mission that is deeply embedded in understanding and ad...

Read More
1 Min Read

‍Birmingham, AL - January 30, 2024 – Acclinate, a trailblazer in advancing health equity through inclusive research, is thrilled to announce its win i...

Read More
Five Ways Pharma Can Support the Importance of Diversity in Healthcare
4 Min Read

In the U.S., Black Americans are three times more likely to die from asthma than whites. There are a number of complex factors that play into this dis...

Read More
Diversity in Healthcare & Clinical Research: Challenges & Opportunities
4 Min Read

Healthcare has a longstanding history of underrepresentation of communities of color. It often begins with the clinical trial process, where longstand...

Read More
Acclinate and Egality Sciences Unite for Health Equity in Hispanic and African American Communities
2 Min Read

In a milestone effort to address the historic underrepresentation of Hispanic and African American communities in clinical research, Acclinate and Ega...

Read More
Unveiling the Path to Inclusivity: DE&I in Clinical Research
1 Min Read

In the dynamic realm of clinical research our commitment to Diversity, Equity, and Inclusion (DE&I) stands as a cornerstone for positive change. A...

Read More
Clinical Trial Diversity: What Does It Really Mean?
3 Min Read

Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t...

Read More
Acclinate Collaborates with Merck to Increase Clinical Trial Diversity
1 Min Read

Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h...

Read More
Clinical Trial Diversity: Unpacking the FDA’s Latest Draft Guidance
3 Min Read

Over the last year and a half, there has been renewed interest from research sponsors to increase diversity in clinical trials. But what is behind thi...

Read More
Celebrating Jasmine Leonard: Acclinate's First NOW Health Equity Award Recipient
2 Min Read

Why NOW? At Acclinate, we believe that the present moment is the most powerful time to drive change. This is why we established the NOW Award, a recog...

Read More
Acclinate partners with Alabama Regional Medical Services
2 Min Read

Acclinate, a leading digital health startup specializing in health equity through inclusive research, is proud to announce a strategic partnership wit...

Read More
Acclinate Hosts Educational Sessions on Artificial Intelligence and Machine Learning (AI/ML)
1 Min Read

BIRMINGHAM, Ala., April 13, 2023 – Acclinate, a digital health company specializing in accessing and engaging communities of color to make better info...

Read More
Acclinate and Savvy Partner to Empower Communities of Color Through Equitable Paid Research Opportunities
2 Min Read

The partnership was formed when the two companies connected on a shared purpose – shaping community experiences through inclusive health opportunities...

Read More
Trialbee and Acclinate to Host Webinar on the 5 Key Trends Poised to Significantly Improve Clinical Trial Patient Diversity in 2023
1 min read

Trialbee and Acllinate will present an informational webinar discussing 5 key trends in diversity for clinical trials in 2023. The webinar aims to pro...

Read More
2 Min Read

CHAPEL HILL, N.C. & BIRMINGHAM, A.L. — Dec. 13, 2022 — Trialbee, the leader in data and technology-based patient recruitment and enrollment for cl...

Read More
NOWINCLUDED Named to Inc.’s 2022 Best in Business List
1 Min Read

Being named to the Inc. 2022 Best in Business list in the Southeast Region category is a major accomplishment for NOWINCLUDED. Recognition of this mag...

Read More
Shayla Wilson joins the Acclinate team
1 Min Read

Acclinate, a leading digital health company, announced today the appointment of Shayla Wilson as Head of Community and Digital Engagement.

Read More
Acclinate selected as an Awardee of Johnson & Johnson's Maternal-fetal Immune Disorders QuickFire Challenge
1 min read

Acclinate has been selected as an awardee in the Maternal-fetal Immune Disorders Quickfire Challenge. The QuickFire Challenges are managed by Johnson ...

Read More
Lightship® and Acclinate Announce Partnership
1 Min Read

Today, we announced our partnership with Lightship®, a leading virtual-first and hybrid provider of clinical research solutions. As partners, we will ...

Read More
Acclinate Wins DPHARM Idol Disrupt 2022
1 min read

DPHARM Idol is an annual competition that recognizes disruptive companies on their technologies and services for their quality, especially for the ben...

Read More
AI/ML: Hero or Villain
3 Min Read

After overhearing a conversation about my company, my 5-year-old niece asked between bites of frosted flakes, “What is A I M L?” I thought about flexi...

Read More
Acclinate's system now patent pending
1 min read

Did you know that Acclinate's system and method of using intelligent AI-based automated determination of clinical trial participation is now patent–pe...

Read More
Clinical Trial Diversity Webinar
1 min read

Achieving sufficient affective trust is necessary for communities of color to feel comfortable participating in clinical research.

Read More
Assessing Pharma's Response to New FDA Guidance on Clinical Trial Diversity
4 Min Read

Today, the U.S. Food and Drug Administration took an important step to increase racial and ethnic diversity in clinical trials by releasing new draft ...

Read More
Camille Pope joins the Acclinate team
1 Min Read

Birmingham, AL ( April 18, 2022) - Acclinate, a leading digital health company, announced the appointment of Camille Pope, PharmD as Chief Medical Lea...

Read More
e-DICT Transforms Clinical Trial Recruitment
2 Min Read

It is common for pharmaceutical companies to carry out thousands of research and clinical trials every year to test new products and drugs. As is the ...

Read More
Healthcare Leaders Join Forces to Transform Digital Clinical Trials Through DEI
1 min read

‍ The Digital Medicine Society (DiMe) announced today a new collaboration with Acclinate, Amgen, GSK, Lightship, Medable, Rubix LS, Sage Bionetworks, ...

Read More
Why Does Minority Participation in Clinical Trials Matter?
3 Min Read

While people of color make up nearly half of the United States population, only a small percentage of them choose to participate in clinical trials – ...

Read More
Time for an industry metric to assess clinical trial diversity
3 Min Read

Racial and ethnic minorities now make up over 42% of the U.S. population. However, the statistics are alarming when we look at corresponding racial an...

Read More
Increased Black Representation
1 Min Read

A medical breach of trust is something that lingers in the minds of Black Americans. From the Tuskegee study to modern mistreatment, the racial landsc...

Read More
Why Black Participation is Important
1 Min Read

Thanks to the endeared Henrietta Lacks, a woman whose cervical cancer cells have majorly contributed to numerous scientific and medical breakthroughs ...

Read More
Why Diversity Initiatives Fail in Clinical Trials
4 Min Read

According to a recent study published in the journal Gastroenterology, Blacks and Hispanics remain noticeably absent from pancreatic cancer clinical t...

Read More
Beacon of hope shines bright on Birmingham
4 Min Read

Dora and I moved to Birmingham in 1993. I was a newly minted Ph.D. from University of Georgia, where I met Dr. Khris McAllister, former Chair of the M...

Read More
Clinical Trials As A Best Treatment Option - Acclinate
2 Min Read

As new trials continue to improve treatment options for patients with all types of cancer, it’s “never too soon to be talking about clinical trials” w...

Read More
Cox Enterprises Social Impact Accelerator Class 2021 - Acclinate
2 Min Read

ATLANTA, Jan. 25, 2021 /PRNewswire/ -- Cox Enterprises has announced the 2021 class of the Cox Enterprises Social Impact Accelerator powered by Techst...

Read More